Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

NCT00098618 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions

DRUG: sorafenib tosylate
BIOLOGICAL: recombinant interferon alfa
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)